An article authored by Ash Bullement and Anthony Hatswell has been published in Pharmacoeconomics Open regarding the cost-effectiveness of avelumab for the treatment of metastatic Merkel cell carcinoma. The analysis provides a summary of the cost-effectiveness model submitted as part of NICE’s technology appraisal of avelumab, including the use of spline-based survival models and time-to-death based utilities. You can find the open-access article by following this Link
An article authored by Ash Bullement has been published in the Journal of Medical Economics on the topic of survival extrapolation for patients treated with cancer immunotherapies. The article presents a review of extrapolation methods presented in company submissions to NICE, and assesses the accuracy of these extrapolations compared with later data. You can read the article for free by following this Link
While quite different to our usual publication work, Anthony has had an article published in Significance, the magazine of the Royal Statistical Society (RSS) on the probability of getting a London Marathon place through the public ballot. The article discusses the increasing popularity of the London Marathon, and the potential reasons for the recent surge in popularity. You can read the article for free online by following this Link
Ash and Anthony will be at ISPOR Asia Pacific in Tokyo for the next few days. Ash has a podium on Monday in the session on modelling methods (discussing the correct methodology for implementation of background mortality), whilst Anthony will be taking part in an issue panel Tuesday on collaboration between companies.